RU2007118523A - Производные индола и бензимидазола - Google Patents
Производные индола и бензимидазола Download PDFInfo
- Publication number
- RU2007118523A RU2007118523A RU2007118523/04A RU2007118523A RU2007118523A RU 2007118523 A RU2007118523 A RU 2007118523A RU 2007118523/04 A RU2007118523/04 A RU 2007118523/04A RU 2007118523 A RU2007118523 A RU 2007118523A RU 2007118523 A RU2007118523 A RU 2007118523A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- benzimidazol
- group
- methylpropyl
- aminopropyl
- Prior art date
Links
- 0 C*C(c1cc([n]nc2)c2cc1)=O Chemical compound C*C(c1cc([n]nc2)c2cc1)=O 0.000 description 4
- SIIUTJNQOCSWNP-UHFFFAOYSA-N CC(C)C(C[n]1cncc1)=O Chemical compound CC(C)C(C[n]1cncc1)=O SIIUTJNQOCSWNP-UHFFFAOYSA-N 0.000 description 1
- PRZLQSXAYCLZOQ-UHFFFAOYSA-N CC[n]1nc(C)cc1C(C(C)(C)C)=O Chemical compound CC[n]1nc(C)cc1C(C(C)(C)C)=O PRZLQSXAYCLZOQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62038504P | 2004-10-19 | 2004-10-19 | |
| US60/620,385 | 2004-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007118523A true RU2007118523A (ru) | 2008-11-27 |
Family
ID=36123937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007118523/04A RU2007118523A (ru) | 2004-10-19 | 2005-10-14 | Производные индола и бензимидазола |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8008335B2 (enExample) |
| EP (2) | EP1807399A2 (enExample) |
| JP (1) | JP2008517057A (enExample) |
| KR (1) | KR20070072598A (enExample) |
| CN (1) | CN101233115A (enExample) |
| AU (1) | AU2005301133A1 (enExample) |
| BR (1) | BRPI0517314A (enExample) |
| CA (1) | CA2584979A1 (enExample) |
| MX (1) | MX2007004699A (enExample) |
| RU (1) | RU2007118523A (enExample) |
| WO (1) | WO2006049835A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3947758B2 (ja) * | 2003-03-07 | 2007-07-25 | アストラゼネカ アクチボラグ | 新規縮合ヘテロサイクル及びその使用 |
| EP1773830A1 (en) * | 2004-07-22 | 2007-04-18 | AstraZeneca AB | Fused pyrimidones useful in the treatment and the prevention of cancer |
| UY29070A1 (es) * | 2004-08-18 | 2006-03-31 | Astrazeneca Ab | Enantiómeros de heterocíclicos fusionados y sus usos |
| CA2584979A1 (en) * | 2004-10-19 | 2006-05-11 | Novartis Vaccines And Diagnostics, Inc. | Indole and benzimidazole derivatives |
| US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
| US7902240B2 (en) * | 2006-11-13 | 2011-03-08 | Novartis Ag | Substituted pyrazole and triazole compounds as KSP inhibitors |
| EP2106399A2 (en) * | 2007-01-05 | 2009-10-07 | Novartis AG | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
| DE102007037579B4 (de) | 2007-08-09 | 2012-05-16 | Emc Microcollections Gmbh | Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| JP2012500260A (ja) * | 2008-08-18 | 2012-01-05 | イェール・ユニヴァーシティー | Ｍｉｆモジュレーター |
| HRP20140754T2 (hr) | 2009-06-29 | 2015-07-17 | Incyte Corporation | Pirimidinoni kao inhibitori pi3k |
| AR079529A1 (es) * | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| US8748626B2 (en) * | 2010-04-15 | 2014-06-10 | Novartis Ag | Oxazole and thiazole compounds as KSP inhibitors |
| KR20130100056A (ko) | 2010-04-15 | 2013-09-09 | 노파르티스 아게 | Ｋｓｐ 억제제로서의 트리아졸 화합물 |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| WO2012087881A1 (en) | 2010-12-20 | 2012-06-28 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| LT3196202T (lt) | 2011-09-02 | 2019-07-10 | Incyte Holdings Corporation | Heterociklilaminai, kaip pi3k slopikliai |
| CN102627578B (zh) * | 2011-10-20 | 2014-06-11 | 南京大学 | 苯基苄胺类化合物及其应用 |
| EA026368B1 (ru) | 2011-12-21 | 2017-03-31 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| CN102603544A (zh) * | 2012-04-06 | 2012-07-25 | 南京大学 | 一种抗炎化合物、其制备及其用途 |
| AU2013307337B2 (en) | 2012-08-28 | 2018-07-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
| CN105189453B (zh) | 2013-02-28 | 2018-04-10 | 爱尔兰詹森科学公司 | 氨磺酰基‑芳基酰胺及其作为用于乙型肝炎治疗的药物的用途 |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| BR112015028538A2 (pt) | 2013-05-17 | 2017-07-25 | Janssen Sciences Ireland Uc | derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b |
| WO2014200872A1 (en) | 2013-06-09 | 2014-12-18 | Rjs Biologics Llc | Pharmaceutical compounds targeted by mif affinity-tethered moieties |
| CA2935719C (en) | 2013-07-25 | 2021-11-02 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| AU2014338947B2 (en) | 2013-10-23 | 2018-02-22 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
| JP6495929B2 (ja) | 2014-02-06 | 2019-04-03 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイルピロールアミド誘導体およびｂ型肝炎の治療のための医薬としてのその使用 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| CN117736209A (zh) | 2015-02-27 | 2024-03-22 | 因赛特控股公司 | Pi3k抑制剂的盐及其制备方法 |
| AU2016232801A1 (en) | 2015-03-19 | 2017-10-12 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| BR112018071048A2 (pt) | 2016-04-15 | 2019-05-07 | Janssen Sciences Ireland Uc | combinações e métodos que compreendem um inibidor da montagem de capsídeos |
| WO2018081361A1 (en) * | 2016-10-28 | 2018-05-03 | Children's Hospital Medical Center | Methods and compositions for treatment of myelodyspastic syndromes and/or acute myleoid leukemias |
| MA52019A (fr) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Co | Schéma posologique de modulateur d'assemblage de capside |
| PE20211208A1 (es) | 2018-06-01 | 2021-07-05 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k |
| CA3127152A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| AU2023375996A1 (en) * | 2022-11-07 | 2025-06-19 | Merck Patent Gmbh | Substituted bi-and tricyclic hset inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| JPH03200961A (ja) * | 1989-10-03 | 1991-09-02 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JPH04184433A (ja) * | 1990-11-20 | 1992-07-01 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JPH04321046A (ja) * | 1991-02-15 | 1992-11-11 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| US5185450A (en) | 1991-02-19 | 1993-02-09 | University Of South Florida | Tetrazolium compounds for cell viability assays |
| JP2847273B2 (ja) * | 1991-11-22 | 1999-01-13 | 富士写真フイルム株式会社 | カラー画像形成方法 |
| JPH063775A (ja) * | 1992-06-22 | 1994-01-14 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6358949B1 (en) * | 1999-04-02 | 2002-03-19 | Neurogen Corporation | Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors |
| CA2369549A1 (en) | 1999-04-02 | 2000-10-12 | Robert W. Desimone | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| US6271241B1 (en) * | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| EP1686120A3 (en) | 1999-10-27 | 2007-05-30 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| KR20030020960A (ko) | 2000-08-01 | 2003-03-10 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | 이미다졸일 유도체 |
| WO2002028839A1 (en) | 2000-10-06 | 2002-04-11 | Neurogen Corporation | Benzimidazole and indole derivatives as crf receptor modulators |
| US20070004713A1 (en) * | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
| WO2002056880A1 (en) | 2001-01-19 | 2002-07-25 | Cytokinetics, Inc. | Triphenylmethane kinesin inhibitors |
| US6992082B2 (en) | 2001-01-19 | 2006-01-31 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| US7060705B2 (en) | 2001-11-07 | 2006-06-13 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003043995A1 (en) | 2001-11-20 | 2003-05-30 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| CA2467916A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7378411B2 (en) | 2001-12-06 | 2008-05-27 | Merck & Co., Inc. | Substituted thienopyrimidinones as a mitotic kinesin inhibitor |
| EP1481077B1 (en) | 2001-12-06 | 2009-11-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7244723B2 (en) | 2001-12-06 | 2007-07-17 | Merck & Co., Inc. | Substituted furopyrimidinones as a mitotic kinesin inhibitors |
| JP4391825B2 (ja) | 2001-12-06 | 2009-12-24 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| US6906075B2 (en) | 2002-01-10 | 2005-06-14 | Neurogen Corp. | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| JP2005532991A (ja) * | 2002-01-10 | 2005-11-04 | ニューロジェン・コーポレーション | メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ |
| US7009049B2 (en) | 2002-02-15 | 2006-03-07 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| CA2478068C (en) | 2002-03-08 | 2011-02-08 | Merck & Co., Inc. | Dihydropyrazole compounds useful for treating or preventing cancer |
| US7166595B2 (en) | 2002-05-09 | 2007-01-23 | Cytokinetics, Inc. | Compounds, methods and compositions |
| US7214800B2 (en) | 2002-05-09 | 2007-05-08 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1507534A4 (en) | 2002-05-10 | 2006-11-08 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| AU2003231799A1 (en) | 2002-05-23 | 2003-12-12 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7038048B2 (en) | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
| JP4377323B2 (ja) | 2002-06-14 | 2009-12-02 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| JP4463679B2 (ja) | 2002-06-14 | 2010-05-19 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| EP1551962A4 (en) | 2002-07-08 | 2007-08-01 | Merck & Co Inc | MITOTIC KINESIN BINDING CENTER |
| DE60326248D1 (de) | 2002-07-17 | 2009-04-02 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen |
| JP2006501201A (ja) | 2002-07-23 | 2006-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| EP1539180A4 (en) | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| WO2004024086A2 (en) | 2002-09-13 | 2004-03-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| US20070054921A1 (en) * | 2003-06-05 | 2007-03-08 | Davies Ian W | Substituted indoles and a process for preparing substituted indoles |
| JP2007509082A (ja) * | 2003-10-22 | 2007-04-12 | アルピダ エー／エス | ペプチドデホルミラーゼ阻害剤としてのベンゾイミダゾール誘導体類およびそれらの使用 |
| CA2584979A1 (en) * | 2004-10-19 | 2006-05-11 | Novartis Vaccines And Diagnostics, Inc. | Indole and benzimidazole derivatives |
-
2005
- 2005-10-14 CA CA002584979A patent/CA2584979A1/en not_active Abandoned
- 2005-10-14 KR KR1020077011415A patent/KR20070072598A/ko not_active Withdrawn
- 2005-10-14 WO PCT/US2005/036803 patent/WO2006049835A2/en not_active Ceased
- 2005-10-14 CN CNA2005800402742A patent/CN101233115A/zh active Pending
- 2005-10-14 EP EP05851219A patent/EP1807399A2/en not_active Withdrawn
- 2005-10-14 JP JP2007537929A patent/JP2008517057A/ja active Pending
- 2005-10-14 MX MX2007004699A patent/MX2007004699A/es not_active Application Discontinuation
- 2005-10-14 EP EP10181182A patent/EP2275412A1/en not_active Withdrawn
- 2005-10-14 US US11/665,956 patent/US8008335B2/en not_active Expired - Fee Related
- 2005-10-14 AU AU2005301133A patent/AU2005301133A1/en not_active Abandoned
- 2005-10-14 BR BRPI0517314-0A patent/BRPI0517314A/pt not_active IP Right Cessation
- 2005-10-14 RU RU2007118523/04A patent/RU2007118523A/ru not_active Application Discontinuation
- 2005-10-14 US US11/251,440 patent/US7608723B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2275412A1 (en) | 2011-01-19 |
| US20080317744A1 (en) | 2008-12-25 |
| BRPI0517314A (pt) | 2008-10-07 |
| JP2008517057A (ja) | 2008-05-22 |
| WO2006049835A2 (en) | 2006-05-11 |
| AU2005301133A1 (en) | 2006-05-11 |
| CA2584979A1 (en) | 2006-05-11 |
| US7608723B2 (en) | 2009-10-27 |
| MX2007004699A (es) | 2007-06-14 |
| CN101233115A (zh) | 2008-07-30 |
| EP1807399A2 (en) | 2007-07-18 |
| WO2006049835A3 (en) | 2007-11-22 |
| US20060084687A1 (en) | 2006-04-20 |
| US8008335B2 (en) | 2011-08-30 |
| KR20070072598A (ko) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007118523A (ru) | Производные индола и бензимидазола | |
| JP2008517057A5 (enExample) | ||
| JP2020503299A5 (enExample) | ||
| RU2006145336A (ru) | Замещенные производные хинолина, как ингибиторы митотического кинезина | |
| JP2008502721A5 (enExample) | ||
| RU2011121665A (ru) | Производные 7-гидроксибензимидазол-4-илметанона и содержащие их ингибиторы рвк | |
| WO2019147862A1 (en) | Chemokine receptor modulators and uses thereof | |
| JP2012510989A5 (enExample) | ||
| JP2005508967A5 (enExample) | ||
| JP2015523390A (ja) | 置換型ピラゾロン化合物及び使用方法 | |
| JP2021501145A5 (enExample) | ||
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2005511531A5 (enExample) | ||
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| BRPI0810911A2 (pt) | Compostos com atividade anticâncer | |
| CN104114169A (zh) | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 | |
| JP2004537564A5 (enExample) | ||
| ME01207B (me) | Derivati hinolina za tretiranje latentne tuberkuloze | |
| JP2018518522A5 (enExample) | ||
| JP2010515750A5 (enExample) | ||
| JP2002523511A5 (enExample) | ||
| WO2010037081A1 (en) | Melanocortin receptor-specific spiro-piperidine compounds | |
| EA001740B1 (ru) | Способ лечения обычной простуды или аллергического ринита | |
| JP2004526699A5 (enExample) | ||
| CN104023715A (zh) | 激酶抑制剂的副作用降低剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100125 |